Product Description
SBT6290 is a product candidate comprised of a selective TLR8 agonist conjugated to a Nectin4-specific monoclonal antibody, designed for systemic delivery and tumor-localized activation of myeloid cells. (Sourced from: https://silverbacktx.com/wp-content/uploads/Silverback_SBT6290-Poster_SITC2020.pdf)
Mechanisms of Action: TLR8 Agonist
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Silverback Therapeutics
Company Location: SEATTLE WA 98109
Company CEO: Laura Shawver
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Transitional Cell Carcinoma|Squamous Cell Carcinoma|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SBT6290-101 | P2 |
Withdrawn |
Triple Negative Breast Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Non-Small-Cell Lung Cancer |
2022-03-31 |
57% |